Linklaters advises EIC Fund on its participation in the Series B equity funding round of Carthera

This round of financing will enable Carthera, a medtech and spin-off from Sorbonne University and developer of SonoCloud®, an innovative ultrasound-based medical device to treat a wide range of brain disorders, to launch the first pivotal multicenter trial with its SonoCloud technology. These funds will also enable it to continue developing its clinical pipeline and technology. The EIC Fund has notably invested alongside Panakès Partners, Relyens Innovation Santé (Turenne Santé) et Supernova Invest via son fonds Supernova 2.

Established in June 2020, the EIC Fund is a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments (between €500,000 and €15m) in European high impact and deep tech start-ups and scale ups.

Since its creation, Linklaters has advised EIC Fund on more than twenty investments in European startups, including PASQAL, CorWave, Aledia, Sileane, Xenothera, Antofénol, Novolyze, XSun, Rosi, Minuendo, Hiber, EpiEndo Pharmaceuticals, NIL Technology, Trisol Medical et Kahun Medical.

The Linklaters team in Paris was led by Corporate/M&A partner Mehdi Boumedine and associate Marguerite Vergez de Heine.